| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total operating expenses | 84,304 | - |
| Loss from operations | -84,304 | - |
| Interest income | 7,088 | - |
| Other expense | -40 | - |
| Total other (income) expense | 7,048 | - |
| Net loss | -77,256 | -54,427 |
| Depreciation | 219 | 161 |
| Amortization of right-of-use assets - operating | 786 | 518 |
| Stock-based compensation | 14,207 | 9,606 |
| Accretion of marketable securities, net | -3,970 | -2,907 |
| Prepaid expenses and other assets | -3,931 | -1,988 |
| Operating lease liabilities | -770 | -500 |
| Accounts payable | -2,135 | -2,236 |
| Accrued expenses | 485 | 802 |
| Net cash used in operating activities | -64,503 | -46,995 |
| Purchases of marketable securities, available-for-sale | 88,122 | 53,348 |
| Proceeds from maturities of marketable securities, available-for-sale | 156,888 | 105,013 |
| Purchases of property and equipment | 108 | 58 |
| Net cash provided by (used in) investing activities | 68,658 | 51,607 |
| Proceeds from exercise of stock options | 203 | - |
| Proceeds from issuance of common stock under employee stock purchase plan | 68 | 68 |
| Net cash provided by financing activities | 271 | 68 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | 284 | 361 |
| Net increase in cash, cash equivalents and restricted cash | 4,710 | 5,041 |
| Cash and cash equivalents at beginning of period | 28,235 | - |
| Cash and cash equivalents at end of period | 32,945 | - |
Ventyx Biosciences, Inc. (VTYX)
Ventyx Biosciences, Inc. (VTYX)